STUDY OF EFFICACY OF MODERN FLUOROQUINOLONES AGAINST AGENT OF GLANDERS IN EXPERIMENTS IN VIVO


Cite item

Full Text

Abstract

Rfloxacin, gemifloxacin, levofloxacin and moxifloxacin were highly effective for urgent prophylaxis and treatment of glanders. Materials and methods. Golden hamsters of both sexes, with weight 80 — 100 g, were inoculated with 100 LD 50 of 48-hour agar culture of Burkholderia mallei (strain Ц-5). Commercial preparations of 2 — 4 th generations of fluoroquinolones: sparfloxacin (Sparflo, India), gemifloxacin (Faktiv, Russia), moxifloxacin (Avelox, Germany), pefloxacin (Abactal, Slovenia), levofloxacin (Eleflox, India), lomefloxacin (Lomeflox, India), ofloxacin (Russia). Urgent prophylaxis started 3 hours after inoculation with duration of 10 days, whereas treatment started 24 hours after inoculation with duration of 15 days. Dayly dose of pefloxacin, ciprofloxacin, ofloxacin was divided on 2 parts, which were administered with 12-hour interval; other drugs were administered once a day. Results. All studied drugs, excluding lomefloxacin, were highly effective for urgent prophylaxis and treatment of experimental glanders and provided 80 — 100% protection. Conclusion. Third-fourth generations of fluoroquinolones: sparfloxacin, levofloxacin, moxifloxacin, gemifloxacin were highly effective against agent of glanders in in vivo experiments. They are promising drugs for the development of schemes for urgent prophylaxis and treatment of glanders in humans.

About the authors

T. A Bondareva

Central Research Institute of Ministry of Defense of Russia, Kirov, Russia

I. V Borisevich

Central Research Institute of Ministry of Defense of Russia, Kirov, Russia

V. B Kalininsky

Central Research Institute of Ministry of Defense of Russia, Kirov, Russia

V. P Bondarev

Central Research Institute of Ministry of Defense of Russia, Kirov, Russia

O. O Fomenkov

Central Research Institute of Ministry of Defense of Russia, Kirov, Russia

References

  1. Владимиров В.Г. Расчет количества лекарственных препаратов на поверхность тела как один из способов определения равноэффективных доз для животных и человека. Фармакол. токсикол. 1976, 1: 123—128.
  2. Вязьмина Т.Н., Тихонов Н.Г., Алексеев В.В. Патогенез, патологическая анатомия и патологическая морфология сапа. В: Сап. Н.Г.Тихонова (ред.). Волгоград, 1995, с. 50—72.
  3. Илюхин В.И., Батманов В.П., Лозовая Н.А. Клиника и лечение сапа. Там же, с. 84—99.
  4. Лобзин Ю.В., Лукин Е.П., Усков А.И. Некоторые аспекты биотерроризма. Мед. акад. журн. 2001, 3 (1): 3—11.
  5. Онищенко Г.Г. Противодействие биологическому терроризму. Практическое руководство по противоэпидемическому обеспечению. М., Петит-А, 2003.
  6. Онищенко Г.Г. Контроль и ликвидация инфекционных заболеваний — стратегическое направление здравоохранения. Журн. микробиол. 2002, 4: 3—16.
  7. Онищенко Г.Г. Меры по противодействию биологическому терроризму в Российской Федерации. Там же. 2005, 4: 33—37.
  8. Стрегунский Л.С., Белоусов Ю.К., Козлов С.Н. Практическое руководство по антиинфекционной терапии. М., 2002.
  9. Экстренная профилактика и лечение опасных инфекционных заболеваний. Метод. ук. М., 2000.
  10. Appelbaum P.C., Hunter P.A. The fluorguinolone antibacterials: past, present and future perspectives. Intern. J. Antimicrob. Agents. 2000, 16: 5—15.
  11. Drusane G.L., Johnson D.E., Rosen M., Standiford H.C. Pharmacodynamics of a fluorguinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 1993, 37: 483—490.
  12. Heddle J., Maxwell A. Quinoione—binding pocket of DNA gyrase: role of Gyr B. Ibid. 2002, 46: 1805—1815.
  13. Lubash A., Keller I., Borner K. et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, tvovafloxacin, levofloxacin, moxifloxacin after single oral administration in healthy volunteers. Ibid. 2000, 44: 2600—2603.
  14. Ruiz J. Mechanisms of resistance to guinolones: target alterations, decreased accumulations and DNA gyrase protection. Ibid. 2003, 51: 1109.
  15. Tillotson G.S. Quinolones: Structure—activity relationships and future predictions. J. Med. Microbiol. 1996, 44: 320—324.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bondareva T.A., Borisevich I.V., Kalininsky V.B., Bondarev V.P., Fomenkov O.O.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies